William Moss, MD
- Head of Epidemiology, IVAC
- Division: Infectious Disease Epidemiology
- Molecular Microbiology and Immunology (Joint)
- International Health (Joint)
Center & Institute Affiliations
- Global Health, Center for
- International Vaccine Access Center (IVAC)
- Malaria Research Institute
- Vaccine Initiative, Johns Hopkins
615 N. Wolfe Street
Baltimore, Maryland 21205
MD, Columbia University, 1984
MPH, Columbia University, 1995
William Moss is a Professor in the Departments of Epidemiology, International Health and Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health and Head of Epidemiology at the International Vaccine Access Center. He is a pediatrician with subspecialty training in infectious diseases, and has worked in Ethiopia, Kenya, South Africa, Zambia, Zimbabwe and India among other countries. His broad research interests are the epidemiology and control of childhood infections in resource-poor countries. The specific focus of his current research is in understanding the impact of the HIV epidemic on measles control and eradication, the epidemiology and control of malaria in southern Africa, and the care and treatment of HIV-infected children in rural Zambia.
Honors and Awards
1999-2001 Wyeth-Lederle Vaccines and Pediatrics Young Investigator Award in Vaccine Development presented by the Infectious Disease Society of America
2001 The Gustave J. Martin Innovative Research Fund Fellow, Johns Hopkins University Bloomberg School of Public Health Faculty Innovation Fund
2007-2008 Advising, Mentoring and Teaching Recognition Award. Student Assembly Honors & Awards Committee. Bloomberg School of Public Health
- Infectious diseases, vaccine-preventable diseases, infectious disease epidemiology, child health, pediatrics, measles, HIV, malaria, complex emergencies, Africa, India
Publications of greatest interest
Bobat R, Coovadia H, Stephen C, Naidoo KL, McKerrow N, Black RE, Moss WJ. Safety and efficacy of zinc supplementation in HIV-infected children: randomized, double-blind, placebo-controlled trial. Lancet 2005;366:1862-7.
Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler J, Audet S, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JR, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT. Immunogenicity of standard-titre measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007;196;347-55.
Lowther SA, Curriero FC, Kalish B, Shields TM, Monze M, Moss WJ. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. Lancet 2009;373:1025-32.
Rainwater-Lovett K, Nkamba H, Mubiana-Mbewe M, Bolton-Moore C, Moss WJ. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak: a prospective cohort study. J Infect Dis 2013; 208:1747-55. PMCID: PMC3814842